logo

For the Inventor, By the Inventor

Kansas City, MO, United States of America

Biomed Valley Discoveries, Inc.


USPTO Granted Patents = 42

% Expired Patents = 7.1


Trademarks = 3

Forward Citations = 71

Loading Chart...
Loading Chart...

33 inventors (with patents filed for the assignee):

goldMedal Saurabh Saha (35 out of 39 patents)

silverMedal Dean Welsch (22 out of 22 patents)

bronzeMedal Gary DeCrescenzo (21 out of 21 patents)

4.  Xiaoyan Michelle Zhang (16 out of 17 patents)

5.  Zhongyu Zhu (15 out of 54 patents)

6.  Dimiter Stanchev Dimitrov (15 out of 102 patents)

7.  Jeffrey James Roix (11 out of 11 patents)

8.  Brad St Croix (10 out of 17 patents)

9.  Enrique Zudaire (10 out of 13 patents)

10.  Rossitza Gueorguieva Alargova (5 out of 24 patents)

11.  Irina Nikolaevna Kadiyala (5 out of 19 patents)

12.  Petinka I Vlahova (5 out of 27 patents)

13.  Stephan X M Boerrigter (5 out of 5 patents)

14.  Alexander Aronov (5 out of 13 patents)

15.  Ali Keshavarz-Shokri (5 out of 33 patents)


Core Competencies:
C. Novyi
Solid Tumors
Anti-CTLA-4 Antibodies
Anti-PD-1 Antibodies
CDK Inhibitors
ERK Inhibitors
Anti-CD276 Antibodies
Tumor-Associated Stroma
Immune Checkpoint Inhibitors
Chimeric Antigen Receptors
PI3K/Akt Pathway
Gliomas

42 patents:

1. 12599593 - METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS (2026-04-14),
2. 12582635 - COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS (2026-03-24),
3. 12433920 - C. novyi for the treatment of solid tumors in non-human animals (2025-10-07),
4. 12427173 - Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies (2025-09-30),
5. 12187698 - Crystalline forms of CHClNO (2025-01-07),
6. 12076324 - Cancer treatments using combinations of CDK and ERK inhibitors (2024-09-03),
7. 11851498 - Anti-CD276 antibodies (B7H3) (2023-12-26),
8. 11679112 - Cancer treatments using combinations of CDK and ERK inhibitors (2023-06-20),
9. 11512138 - Anti-CD276 polypeptides, proteins, and chimeric antigen receptors (2022-11-29),
10. 11439669 - C. novyi for the treatment of solid tumors in humans (2022-09-13),
11. 11390600 - Crystalline forms of CHClNO (2022-07-19),
12. 11246859 - Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers (2022-02-15),
13. 11135225 - Cancer treatments using combinations of CDK and ERK inhibitors (2021-10-05),
14. 11034757 - Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature (2021-06-15),
15. 11033621 - Combination therapies targeting tumor-associated stroma or tumor cells (2021-06-15),
Biomed Valley Discoveries, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative therapies for various diseases. We focus on translating scientific breakthroughs into transformative treatments that can improve patient outcomes. With a dedicated team of researchers and a collaborative approach, we aim to make a significant impact on the future of medicine.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Biomed Valley Discoveries, Inc.
42 Patents

#12 in Kansas City, MO

#102 in Missouri

#8,240 in US

#16,304 in the World

Kansas City, MO (US)
Kansas City, MO, United States of America

Biomed Valley Discoveries, Inc.

Forward Citations = 71

33 inventors:

goldMedal Saurabh Saha (35 out of 39 patents)

silverMedal Dean Welsch (22 out of 22 patents)

bronzeMedal Gary DeCrescenzo (21 out of 21 patents)

4.  Xiaoyan Michelle Zhang (16 out of 17 patents)

5.  Zhongyu Zhu (15 out of 54 patents)

Please report any incorrect information to [email protected]
Loading…